GERN stock sentiment todayGeron Corporation
Sentiment verdict
Gossip first, financials second — HOT at 85% confidence.
Last updated · cached analysis, refreshes periodically
GERN
Geron CorporationGeron has transitioned from a decades-long R&D story to a commercial-stage powerhouse with the FDA approval of Rytelo.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for GERN. Not financial advice.
Price · last 12 months
Gossip
The narrative has shifted from 'perpetual underdog' to a legitimate M&A target following the June 2024 FDA approval of Rytelo for transfusion-dependent anemia in MDS patients. Market chatter focuses on the rapid launch trajectory and the potential for Rytelo to become a standard of care.
- ·FDA approval of Rytelo (imetelstat)
- ·Strong early commercial adoption metrics
- ·Speculation of acquisition by Big Pharma
- ·Expansion into Myelofibrosis (MF) indications
Financial
Post-approval capital raises have fortified the balance sheet, providing a runway into 2026. While currently loss-making due to launch costs, the revenue ramp is expected to be steep as they capture the lower-risk MDS market.
- ·Cash position: ~$430M (pro-forma post-offering)
- ·Revenue growth: Exponential (from zero base)
- ·Operating expenses: Elevated due to sales force build-out
- ·Debt: Manageable via specialized biopharma financing
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Heavy reliance on a single-product platform (imetelstat)
- ·Direct competition from Bristol Myers Squibb's Reblozyl
- ·Potential for future equity dilution if sales ramp slower than expected
Peer temperature
How direct competitors stack up against GERN right now.
- NEUTRALBMYBristol Myers Squibb
COLDER — While Reblozyl is a direct competitor, BMY is a massive value play facing a patent cliff, lacking GERN's explosive growth percentage.
See full analysis → - HOTKRTXKaruna Therapeutics (Acquired)
SIMILAR — Represents the high-premium acquisition path GERN is likely on following successful late-stage clinical data.
See full analysis → - NEUTRALRYTMRhythm Pharmaceuticals
COLDER — Also a commercial-stage biotech, but targeting niche obesity markets with a slower total addressable market (TAM) penetration than GERN's oncology focus.
See full analysis →
- GERN-27.3%
- BMY+0.1%
- KRTX—
- RYTM-2.8%
Analyst price target
Consensus average of 3 analysts · median 4.00
Source: StockAnalysis.com · updated 2026-10-29
AI-generated analysis for informational purposes only. Not financial advice.